Curis to Release Third Quarter 2020 Financial Results and Hold Conference Call on November 10, 2020
Curis, Inc. (NASDAQ: CRIS) will report its third quarter 2020 financial results on November 10, 2020, post market close. The management will conduct a conference call at 4:30 p.m. ET on the same day to discuss the results. The call can be accessed via phone or through the Curis website. Curis is known for developing innovative cancer therapeutics and has several key collaborations, including with Aurigene and Genentech for advanced treatment options and ongoing clinical trials.
- Curis has ongoing clinical trials for multiple therapeutics including CA-4948 in non-Hodgkin lymphoma and AML.
- Collaboration with Genentech for Erivedge commercialization enhances potential revenue.
- None.
LEXINGTON, Mass., Nov. 2, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its third quarter 2020 financial results on Tuesday, November 10, 2020, after the close of US markets. Management will host a conference call on the same day at 4:30 p.m. ET.
To access the live conference call, please dial (888) 346-6389 from the United States or (412) 317-5252 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the financial results conference call will be available on the Curis website shortly after completion of the call.
About Curis, Inc.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including, the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin lymphoma and in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-release-third-quarter-2020-financial-results-and-hold-conference-call-on-november-10-2020-301164715.html
SOURCE Curis, Inc.
FAQ
When will Curis release its third quarter 2020 financial results?
What time is the Curis conference call?
How can I access the Curis conference call?
What is Curis focusing on in its clinical trials?
